已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Repeat hepatectomy versus microwave ablation for solitary and small (≤3 cm) recurrent hepatocellular carcinoma with early or late recurrence: A propensity score matched study

医学 肝细胞癌 倾向得分匹配 微波消融 肝切除术 内科学 外科 肿瘤科 放射科 切除术 烧蚀
作者
Wenqiang Wang,Xing Lv,Jian Li,Jiang Li,Jinlin Wang,Tong Yuan,Junjie Liu,Rong-Hua Zhu,Zhiyong Huang,Erlei Zhang
出处
期刊:Ejso [Elsevier BV]
卷期号:49 (5): 1001-1008 被引量:13
标识
DOI:10.1016/j.ejso.2022.12.016
摘要

Repeat hepatectomy (RH) and microwave ablation (MWA) are frequently used procedures for the treatment of recurrent hepatocellular carcinoma (HCC) after curative resection. This study aimed to compare the long-term outcomes of RH and MWA for solitary and small HCC with early or late recurrence.This retrospective study enrolled patients who underwent RH or MWA for solitary and small (≤3 cm) recurrent HCC at Tongji hospital between April 2006 and December 2020. Propensity score matching (PSM) was further employed to analyze the prognosis of different treatment methods.A total of 256 patients were analyzed, of whom 94 and 162 underwent RH and MWA, respectively. The overall treatment-related complication rate was higher in the RH group. Both recurrence-free survival (RFS) and overall survival (OS) rates of RH were significantly better than those of MWA. Multivariate analysis showed that MWA, early recurrence (within 24 months after initial resection), cirrhosis, and AFP >400 ng/ml were independent risk factors for poor prognoses of recurrent HCC. The stratified analysis demonstrated that MWA and RH had similar long-term outcomes in patients with early recurrence. Nevertheless, MWA had worse RFS and OS than RH in patients with late recurrence. The same results were obtained in the PSM analysis.The long-term outcomes of HCC patients with late recurrence were significantly better than those with early recurrence. RH should be the first choice for solitary small recurrent HCC patients with late recurrence, while MWA should be selected for those with early recurrence.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
雷欣儿发布了新的文献求助10
刚刚
小二郎应助老大爱贴纸采纳,获得10
3秒前
4秒前
小马甲应助sy1639采纳,获得10
5秒前
9秒前
nonoke完成签到 ,获得积分10
9秒前
自觉的迎松完成签到 ,获得积分10
11秒前
11秒前
14秒前
占易形发布了新的文献求助30
17秒前
可耐的善斓完成签到,获得积分10
18秒前
唄肯妮完成签到,获得积分10
19秒前
19秒前
19秒前
20秒前
唄肯妮发布了新的文献求助10
22秒前
迷路的八宝粥完成签到 ,获得积分10
22秒前
rita_sun1969完成签到,获得积分10
23秒前
26秒前
顺利酸奶完成签到 ,获得积分10
28秒前
威武绝山发布了新的文献求助10
29秒前
30秒前
31秒前
占易形发布了新的文献求助10
32秒前
34秒前
37秒前
aaaaa发布了新的文献求助10
38秒前
39秒前
谁跟你嘻嘻哈哈完成签到,获得积分10
40秒前
李爱国应助哈哈采纳,获得10
43秒前
43秒前
43秒前
波波完成签到 ,获得积分10
44秒前
45秒前
嘟嘟发布了新的文献求助10
47秒前
48秒前
孙明浩完成签到 ,获得积分10
48秒前
茗欽完成签到 ,获得积分10
51秒前
卡西法发布了新的文献求助10
51秒前
51秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
Electrode Potentials 550
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6965539
求助须知:如何正确求助?哪些是违规求助? 8647121
关于积分的说明 18338620
捐赠科研通 6417482
什么是DOI,文献DOI怎么找? 3087495
关于科研通互助平台的介绍 2137865
邀请新用户注册赠送积分活动 2064062